An open-labelled, international, multicenter, dose escalating, phase I/II study of SPC2996,an LNA antisense molecule against Bcl-2, in patients with relapsed or refractory chronic lymphocytic leukaemia.
Phase of Trial: Phase I/II
Latest Information Update: 09 Nov 2012
At a glance
- Drugs SPC 2996 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Feb 2011 Actual end date (Dec 2007 ) added as reported by ClinicalTrials.gov.
- 01 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.